Grounding Value-Based Drug Pricing in Population Health

Anna Kaltenboeck¹, Maura Calsyn², Geert W J Frederix³, Justin Lowenthal^{4

5

6}, David Mitchell⁷, Bruce Rector^{4

5}, Ameet Sarpatwari⁸

Affiliations

¹ Drug Pricing Lab, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Center for American Progress, Washington, District of Columbia, USA.
³ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
⁴ Drug Pricing, Value, and Affordability Campaign, Doctors for America, New York, New York, USA.
⁵ Drug Pricing, Value, and Affordability Campaign, Doctors for America, Baltimore, Maryland, USA.
⁶ Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁷ Patients for Affordable Drugs, Washington, District of Columbia, USA.
⁸ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Anna Kaltenboeck et al. Clin Pharmacol Ther. 2020 Jun.

. 2020 Jun;107(6):1290-1292.

doi: 10.1002/cpt.1741. Epub 2020 Jan 17.

Anna Kaltenboeck¹, Maura Calsyn², Geert W J Frederix³, Justin Lowenthal^{4

5

6}, David Mitchell⁷, Bruce Rector^{4

5}, Ameet Sarpatwari⁸

¹ Drug Pricing Lab, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Center for American Progress, Washington, District of Columbia, USA.
³ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
⁴ Drug Pricing, Value, and Affordability Campaign, Doctors for America, New York, New York, USA.
⁵ Drug Pricing, Value, and Affordability Campaign, Doctors for America, Baltimore, Maryland, USA.
⁶ Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁷ Patients for Affordable Drugs, Washington, District of Columbia, USA.
⁸ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

No abstract available

References

1. Kesselheim, A.S., Avorn, A. & Sarpatwari, A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 316, 858-871 (2016).
1. Analysis Group. The biopharmaceutical pipeline: innovative therapies in clinical development. Analysis Group <https://www.analysisgroup.com/uploadedfiles/content/insights/publishing/... (2019). Accessed November 8, 2019.
1. Tang, J., Shalabi, A. & Hubbard-Lucey, V.M. Comprehensive analysis of the clinical immuno-oncology landscape. Ann. Oncol. 29, 84-91 (2018).
1. Voretigene Neparvovec for biallelic RPE65- mediated retinal disease: effectiveness and value. ICER <https://icer-review.org/wp-content/uploads/2017/06/mwcepac_voretigene_fi.... Accessed November 8, 2019.
1. White, N., Pace, M., Johns, A. & Latch, E. What ICER pricing would mean for U.S. drug spend. Managed Care Magazine <https://www.managedcaremag.com/viewpoint/what-icer-pricing-would-mean-us.... Accessed November 8, 2019.